SHUKRAPHARShukra Pharmaceuticals Limited
Convert to ideaHealthcare · Drug Manufacturers - Specialty & Generic
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.2 this quarter.
Momentum from moving averages, Supertrend and RSI.
1 forensic issue found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
1 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹44 Cr | ₹13 Cr | 39.77% | 28.76% | ₹0.29 | 55.0x |
| Q1 FY2027 | ₹24 Cr | ₹13 Cr | 76.74% | 55.06% | ₹0.30 | 43.0x |
| Q4 FY2026 | ₹6 Cr | ₹-2 Cr | -9.65% | -31.80% | ₹-0.04 | -2.4x |
| Q3 FY2026 | ₹39 Cr | ₹20 Cr | 67.21% | 52.03% | ₹0.47 | 93.9x |
| Q2 FY2026 | ₹6 Cr | ₹2 Cr | -21.12% | 40.37% | ₹0.05 | -4.4x |
| Q1 FY2026 | ₹5 Cr | ₹1 Cr | 9.83% | 18.92% | ₹0.02 | 2.0x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Drug Manufacturers - Specialty & Generic
Compare with peers →Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016. Shukra Pharmaceuticals Limited was incorporated in 1993 and is based in Ahmedabad, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.